文献速递胸部肿瘤

加速全面分子分析以优化吸烟史极少的肺癌患者的初始治疗

Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.
PubMed 文献 · J Thorac Oncol · 2019-01-18

本研究针对吸烟史有限的肺癌患者设计了一套加速二代测序(NGS)检测的工作流程,包括从冷冻组织次日提取核酸并将标本在测序时列为高优先级。2017年1月至2018年5月共21例患者参与,活检至NGS结果的中位间隔为10.7天,6例在活检后1周内获得结果。冷冻组织分子分析将分析前时间从3.5天缩短至1.3天(p < 0.0001),实验室内周转时间缩短3天(11.8 vs 8.4个工作日,p < 0.0001);93%的可靶向分子变异患者接受了第一线靶向治疗,从活检至开始治疗的中位时间为19.7天。

要点

  • 冷冻组织次日提取核酸并优先测序的工作流程可将分析前时间从3.5天缩短至1.3天(p < 0.0001)。
  • 该流程使实验室内周转时间缩短3天(11.8 vs 8.4个工作日,p < 0.0001)。
  • 93%的可靶向分子变异患者接受了第一线靶向治疗,活检至开始治疗中位时间19.7天。

核心结论

  • 从冷冻组织提取核酸并进行测序和分析是缩短至匹配治疗时间的实用策略。
  • 对部分肺癌患者 upfront 使用靶向治疗的显著优势为开发加速全面分子分析的工作流程提供了依据。

研究设计与样本

  • 研究设计了允许从冷冻组织次日提取核酸的方案,并将标本在测序时列为高优先级。
  • 2017年1月至2018年5月共21例患者参与加速测序项目。
  • 通过确定活检至NGS结果的间隔来评估该工作流程是否缩短分析前时间和实验室内周转时间,并是否允许快速启动基因型匹配治疗。

主要发现

  • 活检至NGS结果的中位间隔为10.7天。
  • 6例患者在活检后1周内获得结果。
  • 冷冻组织分子分析将分析前时间从3.5天缩短至1.3天(p < 0.0001)。
  • 实验室内周转时间缩短3天(11.8 vs 8.4个工作日,p < 0.0001)。
  • 93%的可靶向分子变异患者接受了第一线靶向治疗。

关键数值与推荐

  • 分析前时间:冷冻组织分子分析为1.3天 vs 3.5天(p < 0.0001)。
  • 实验室内周转时间:8.4个工作日 vs 11.8个工作日(p < 0.0001)。
  • 活检至NGS结果中位间隔:10.7天。
  • 活检至开始治疗中位时间:19.7天。

临床怎么用

  • 作者认为从冷冻组织提取核酸并进行测序和分析是缩短至匹配治疗时间的实用策略。
  • 作者认为部分肺癌患者 upfront 使用靶向治疗的显著优势为开发加速全面分子分析的工作流程提供了依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lung cancer patients with tumors harboring actionable alterations can achieve very durable responses to first-line targeted therapy. However, identifying targetable alterations using next-generation sequencing (NGS) is a complex and time-intensive process. As actionable genetic alterations are enriched in lung cancers arising in patients with limited smoking history, we designed a workflow to expedite NGS testing for this group. METHODS: We developed a protocol to allow for next-day extraction of nucleic acids from frozen tissue. Specimens were designated as high priority during sequencing. We determined the interval between biopsy and NGS results to evaluate whether the workflow reduced the pre-analytical period and in-laboratory turnaround time and allowed for rapid initiation of genotype-matched therapy. RESULTS: Between January 2017 and May 2018, 21 patients participated in the expedited sequencing program. The median interval between biopsy and NGS results was 10.7 days. Six patients received results within 1 week of biopsy. Performing molecular analysis on frozen tissue and prioritizing sequencing and analysis of these specimens reduced the pre-analytical period from 3.5 to 1.3 days (p < 0.0001) and shortened in-laboratory turnaround time by 3 days (11.8 versus 8.4 business days, p < 0.0001). Ninety-three percent of patients with an actionable molecular alteration received first-line targeted therapy. The median time-to-initiation of treatment was 19.7 days from biopsy. CONCLUSIONS: Sequencing and analyzing nucleic acids from frozen tissue is a practical strategy for shortening the time to matched therapy. The significant advantage of upfront treatment with targeted therapies in subsets of lung cancer patients provides rationale for developing workflows that accelerate comprehensive molecular analysis.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dagogo-Jack I, Robinson H, Mino-Kenudson M, et al. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. J Thorac Oncol. 2019. PMID: 30660796. doi:10.1016/j.jtho.2018.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。